CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial by Raymond L. Benza, Philip B. Adamson, Deepak L. Bhatt, Fredrik Frick, Gunnar Olsson, Niklas Bergh, Björn Dahlöf

Get full text